Notice of Closed Meeting, 15031-15032 [2023-04922]
Download as PDF
<![CDATA[
15031
Federal Register / Vol. 88, No. 47 / Friday, March 10, 2023 / Notices
Emerging and Zoonotic Infectious
Diseases (NCEZID), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and
Prevention’s (CDC), National Center for
Emerging and Zoonotic Infectious
Diseases (NCEZID), Division of Global
Migration and Quarantine (DGMQ),
Travelers’ Health Branch (THB) requests
three-year approval for information
collection from international air
travelers that participate in the Travelerbased Genomic Surveillance project.
Genetic variants of SARS–CoV–2 have
been emerging and circulating around
the world throughout the COVID–19
pandemic. Of particular concern are
variants for which there is evidence of
an increase in transmissibility, more
severe disease (for example, increased
hospitalizations or deaths), significant
reduction in neutralization by
antibodies generated during previous
infection or vaccination, reduced
effectiveness of treatments or vaccines,
or diagnostic detection failures.
CDC recommends that all arriving
international travelers get tested before
departing and 3–5 days after travel.
However, this testing is not mandatory
for all travelers. Furthermore, there are
currently few systems that conduct
disease surveillance in the population of
arriving international travelers.
Moreover, as testing and sequencing for
SARS–CoV–2 continue to decline
worldwide, detecting emerging variants
of concern (VOCs) in a timely manner
is becoming more and more difficult.
To address this gap, in September
2021, the THB, in collaboration with
private partners, implemented a
voluntary SARS–CoV–2 genomic
surveillance program with the goal of
early detection of novel VOCs.
Surveillance for new and emerging
variant strains among travelers can
provide researchers and public health
officials critical time to collect
information about the transmissibility,
virulence, and effectiveness of existing
vaccines, diagnostics, and therapeutics.
The project is conducted with external
partners and groups within DGMQ and
across CDC, including the Office of
Advanced Molecular Detection. The
program began at New York’s John F.
Kennedy International Airport in
September 2021 and later expanded to
include Newark Liberty International,
San Francisco International, and
Hartsfield-Jackson Atlanta International
airports. Since November 2022, the
program has expanded to Los Angeles,
Seattle, and Washington Dulles.
Information collection for this project is
currently approved under a Public
Health Emergency PRA Waiver.
The information collection for which
approval is sought is in accordance with
CDC/DGMQ’s mission to reduce
morbidity and mortality among travelers
and to prevent the introduction,
transmission, or spread of
communicable diseases from foreign
countries into the U.S. This mission is
supported by the Section 361 of the
Public Health Service Act regulations
found in 42 Code of Federal Regulations
part 70 and 71. Also supported under
general authorities provided by Sections
301 and 311 in the Public Health
Service Act regulations.
CDC requests OMB approval for an
estimated 46,250 annual burden hours.
There is no cost to respondents other
than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondents
Form name
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
Arriving international traveler ..................................................
Questionnaire .........................
555,000
1
6/60
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2023–04968 Filed 3–9–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
lotter on DSK11XQN23PROD with NOTICES1
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
VerDate Sep<11>2014
17:45 Mar 09, 2023
Jkt 259001
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
CE24–001, Panel B, Grants for Injury
Control Research Centers (ICRC).
Dates: May 17–18, 2023.
Times: 8:30 a.m.–5 p.m., EDT.
Place: Crowne Plaza Atlanta
Perimeter at Ravinia, 4355 Ashford
Dunwoody Road NE, Atlanta, Georgia
30346.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Aisha L. Wilkes, M.P.H., Scientific
Review Officer, National Center for
Injury Prevention and Control, CDC,
4770 Buford Highway NE, Mailstop
S106–9, Atlanta, Georgia 30341;
Telephone: (404) 639–6473; Email:
AWilkes@cdc.gov.
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2023–04923 Filed 3–9–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is
hereby given of the following meeting.
E:\FR\FM\10MRN1.SGM
10MRN1
15032
Federal Register / Vol. 88, No. 47 / Friday, March 10, 2023 / Notices
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
CE24–001, Panel A, Grants for Injury
Control Research Centers (ICRC).
Dates: May 16–17, 2023.
Times: 8:30 a.m.–5 p.m., EDT.
Place: Crowne Plaza Atlanta
Perimeter at Ravinia, 4355 Ashford
Dunwoody Road NE, Atlanta, Georgia
30346.
Agenda: To review and evaluate grant
applications.
FOR FURTHER INFORMATION CONTACT:
Mikel Walters, Ph.D., Scientific Review
Officer, National Center for Injury
Prevention and Control, CDC, 4770
Buford Highway NE, Mailstop S106–9,
Atlanta, Georgia 30341; Telephone:
(404) 639–0913; Email: MWalters@
cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2023–04922 Filed 3–9–23; 8:45 am]
lotter on DSK11XQN23PROD with NOTICES1
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP)–SIP23–001,
Effective Community Conversations
for Influenza and COVID–19 Vaccine
Uptake; Amended Notice of Closed
Meeting
Notice of Closed Meeting
Notice is hereby given of a change in
the meeting of the Disease, Disability,
and Injury Prevention and Control
Special Emphasis Panel (SEP)–SIP23–
001, Effective Community
Conversations for Influenza and
COVID–19 Vaccine Uptake; May 2,
2023, 11:00 a.m.–3:00 p.m., EDT,
teleconference, in the original Federal
Register Notice. The meeting was
published in the Federal Register on
February 13, 2023, Volume 88, Number
29, page 9289.
The meeting is being amended to
change the meeting time and should
read as follows:
Date: May 2, 2023
Time: 10 a.m.–6 p.m., EDT
The meeting is closed to the public.
FOR FURTHER INFORMATION CONTACT:
Catherine Barrett, Ph.D., Scientific
Review Officer, National Center for
Chronic Disease Prevention and Health
Promotion, CDC, 4770 Buford Highway,
Mailstop S107–3, Atlanta, Georgia
30341–3717; Telephone: (770) 718–
7664; Email: CBarrett@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2023–04918 Filed 3–9–23; 8:45 am]
BILLING CODE 4163–18–P
Pursuant to 5 U.S.C. 1009(d), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
CE23–005, Panel B, Research Grants to
Inform Firearm-Related Violence and
Injury Prevention Strategies (R01).
Dates: April 17–18, 2023.
Times: 8:30 a.m.–5 p.m., EDT.
Place: Crowne Plaza Atlanta
Perimeter at Ravinia, 4355 Ashford
Dunwoody Road NE, Atlanta, Georgia
30346.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Aisha L. Wilkes, M.P.H., Scientific
Review Officer, National Center for
Injury Prevention and Control, CDC,
4770 Buford Highway NE, Mailstop
S106–9, Atlanta, Georgia 30341;
Telephone: (404) 639–6473; Email:
AWilkes@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2023–04920 Filed 3–9–23; 8:45 am]
BILLING CODE 4163–18–P
VerDate Sep<11>2014
17:45 Mar 09, 2023
Jkt 259001
PO 00000
Frm 00063
Fmt 4703
Sfmt 9990
E:\FR\FM\10MRN1.SGM
10MRN1
]]>Agencies
[Federal Register Volume 88, Number 47 (Friday, March 10, 2023)]
[Notices]
[Pages 15031-15032]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-04922]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the
following meeting.
[[Page 15032]]
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended, and the Determination of the Director, Strategic
Business Initiatives Unit, Office of the Chief Operating Officer, CDC,
pursuant to Public Law 92-463. The grant applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)--CE24-001, Panel A, Grants for
Injury Control Research Centers (ICRC).
Dates: May 16-17, 2023.
Times: 8:30 a.m.-5 p.m., EDT.
Place: Crowne Plaza Atlanta Perimeter at Ravinia, 4355 Ashford
Dunwoody Road NE, Atlanta, Georgia 30346.
Agenda: To review and evaluate grant applications.
FOR FURTHER INFORMATION CONTACT: Mikel Walters, Ph.D., Scientific
Review Officer, National Center for Injury Prevention and Control, CDC,
4770 Buford Highway NE, Mailstop S106-9, Atlanta, Georgia 30341;
Telephone: (404) 639-0913; Email: [email protected].
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-04922 Filed 3-9-23; 8:45 am]
BILLING CODE 4163-18-P
